CD274 and cervical cancer: The final AGEN1884 trial, NCT03894215 is a randomized, non-comparative, phase II clinical study observing the efficacy and safety of AGEN2034, a PD-L1 inhibitor versus a placebo, and AGEN2034 + AGEN1884 in subjects with advanced cervical cancer after failed chemotherapy.